|Event:||Mar 17 - 21, 2013|
|Anaheim, CA, US|
What's next for shares of Agilent Technology.
Agilent turned in another stellar earnings results.
Previously studies already showed improvement from use of Exelixis's Cabometyx over Pfizer's Sutent in treating kidney cancer patients.
U.S. stock futures are higher on Tuesday.